Sector News

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

May 21, 2022
Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by.

The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.” However, what exactly is being exchanged remains unknown; Kelun has more than a dozen oncology assets, with 11 in clinical trials and three in preclinical testing.

A Merck spokesperson said in an email the company had nothing to add beyond what was released in the disclosure.

Translated from Chinese, the disclosure says Merck will pay $17 million off the top and an additional $30 million after the agreement is formally signed. Kelun stands to earn up to $1.36 billion in cumulative milestones.

It’s not the first time Kelun has made a licensing splash. In 2018, it inked a deal for its midstage PD-L1 antibody with Harbour BioMed for up to $350 million.

As for Merck, the plucking of Kelun’s project comes as it reportedly considers larger M&A plays to capitalize on biotech’s bear market. A few of the names supposedly on the company’s shortlist are Mirati Therapeutics, Strand Therapeutics and Arcturus Therapeutics.

By Max Bayer

Source: fiercebiotech.com

comments closed

Related News

June 8, 2024

Lilly CFO leaves to join Alphabet

Life sciences

Anat Ashkenazi will leave Eli Lilly’s executive suite at the end of July to become CFO and senior vice president of Google and Alphabet. Ashkenazi has been CFO at Lilly since 2021 and originally joined the company in 2001. Over her 23-year career at the Indianapolis-based drugmaker, Ashkenazi also served as controller, CFO of Lilly Research Laboratories and as the finance chief for several global divisions within the company.

June 8, 2024

Edwards Lifesciences to cell Critical Care to BD

Life sciences

Edwards Lifesciences (NYSE: EW) announced it has entered into a definitive agreement to sell its Critical Care product group to BD (Becton, Dickinson and Company), in an all-cash transaction valued at $4.2 billion. With this agreement, Edwards is no longer pursuing the previously announced spin-off of Critical Care.

June 8, 2024

Danaher names Martin Stumpe as chief data and AI officer

Life sciences

The company, which owns diagnostics and life sciences businesses including Beckman Coulter and Cepheid, said the appointment reflects its increasing investment in AI as “a driving force for innovation and productivity.” Danaher is focused on AI by also spending on its internal capabilities and partnering with academic groups.

How can we help you?

We're easy to reach